Anova Reaches 500 Urology Sites Across Global CRO Research Network

• Anova Enterprises, Inc. has expanded its global urology research network to 500 active clinical sites, marking a major CRO milestone.

• The network, powered by the AnovaOS® platform, aims to improve site selection, study start-up, and patient enrollment through digital integration.

Anova Enterprises, Inc. announced that its global urology research network has reached 500 active clinical sites, marking a key milestone for the technology-enabled contract research organization (CRO). The network is delivered through the company’s AnovaOS® platform, which connects urology research sites into a digitally integrated ecosystem. 

The expansion is designed to address longstanding inefficiencies in urology clinical research, including fragmented site infrastructure, inconsistent patient recruitment, and lengthy study start-up timelines. By digitally linking community practices, academic centers, and hospital groups, the CRO aims to standardize performance and enable faster activation of clinical trials. 

AnovaOS® provides capabilities such as digital feasibility assessments, automated study start-up, patient matching, and real-time monitoring. According to the company, these tools are intended to streamline clinical operations, accelerate enrollment, and improve oversight across multi-site studies. 

From a CRO perspective, the network offers sponsors access to a scalable pool of qualified investigators and research sites, supported by centralized coordination and data infrastructure. The company said the model enables more efficient execution of industry-sponsored trials while improving access for patients treated outside major academic centers. 

“Reaching our 500th urology site underscores the need for a modern, connected approach to the conduct of urology research.”

Martin Walsh, President and Co-founder of Anova